Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

This study has been completed.
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group ) Identifier:
First received: December 14, 2005
Last updated: November 25, 2016
Last verified: January 2012

RATIONALE: AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD0530 together with gemcitabine may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of AZD0530 when given together with gemcitabine and to see how well they work in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery.

Condition Intervention Phase
Pancreatic Cancer
Drug: AZD0530
Drug: gemcitabine hydrochloride
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of AZD0530 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Canadian Cancer Trials Group:

Primary Outcome Measures:
  • Response (complete [CR] and partial response [PR] or stable disease [SD]) at 8 weeks [ Time Frame: 4 years ]
    Response is assessed every other cycle and will be reported on at final analysis

Secondary Outcome Measures:
  • Toxicity [ Time Frame: 4 years ]
    Toxicity is assessed from the time of first treatment and final results will be reported at final analysis

Enrollment: 34
Study Start Date: September 2005
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: AZD0530
    Taken daily every 4 weeks
    Drug: gemcitabine hydrochloride
    1000mg/m2 IV weekly
Detailed Description:


Phase I

  • Determine the maximum tolerated dose of AZD0530 when given in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic cancer.
  • Determine the safety and tolerability of this regimen in these patients.
  • Determine toxicity profile and dose-limiting toxicity of this regimen in these patients.
  • Determine pharmacokinetic profile of this regimen in these patients.
  • Correlate the toxicity profile with the pharmacokinetics of this regimen in these patients.

Phase II

  • Determine the objective response rate (partial and complete response) and prolonged stable disease rate in patients treated with this regimen.
  • Determine the median survival, 1-year survival, response or stable disease duration, time to disease progression, clinical benefit response, and progression-free survival of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Correlate changes in serum CTX levels (post-treatment vs baseline) with response and other clinical outcomes in patients treated with this regimen.

OUTLINE: This is a phase I, open-label, multicenter, dose-escalation study of AZD0530 followed by a phase II study.

  • Phase I: Patients receive oral AZD0530 once daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses after achieving complete response or stable partial response. Patients with ongoing stable disease receive up to 6 courses. Patients who discontinue gemcitabine due to unacceptable toxicity or who complete 6 courses of therapy may continue to receive AZD0530 alone in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of AZD0530 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.

  • Phase II: Patients receive AZD0530 at the MTD determined in phase I and gemcitabine as in phase I.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed pancreatic adenocarcinoma

    • Unresectable disease
    • Locally advanced or metastatic disease
  • Clinically or radiologically documented disease

    • Measurable or evaluable disease (phase I)
    • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan (phase II)

      • Measurable lesion must be outside of previously irradiated field if it is the sole site of disease unless there is documented disease progression
  • No known brain metastases


Performance status

  • ECOG 0-2

Life expectancy

  • More than 12 weeks


  • Platelet count ≥ 100,000/mm^3
  • Absolute granulocyte count ≥ 1,500/mm^3


  • Bilirubin normal
  • AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if clearly attributable to liver metastasis)


  • Creatinine normal


  • No active cardiomyopathy
  • No congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • No uncontrolled hypertension
  • No myocardial infarction within the past 12 months


  • No pulmonary disease requiring oxygen supplementation


  • Must not require IV hyperalimentation
  • No uncontrolled inflammatory gastrointestinal (GI) disease (e.g., Crohn's disease or ulcerative colitis)
  • No active peptic ulcer disease
  • No postsurgical malabsorption characterized by uncontrolled diarrhea that results in weight loss and vitamin deficiency
  • No other GI tract disease resulting in an inability to take oral medications
  • Must be able to take oral medication without crushing, dissolving, or chewing tablets
  • Pancreatic enzyme supplementation allowed provided the above conditions are met


  • No immune deficiency
  • No active, uncontrolled, or serious infection
  • No know hypersensitivity to study drugs or their components
  • No known HIV positivity


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of psychiatric illness (e.g., uncontrolled psychotic disorders) or neurologic disorder that would preclude study compliance
  • No other serious medical condition or illness that would preclude study participation
  • No other malignancy within the past 5 years except curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix or bladder



  • No prior chemotherapy except fluorouracil (with or without leucovorin calcium) or gemcitabine given concurrently with radiotherapy as a radiosensitizer

    • At least 4 weeks since prior fluorouracil or gemcitabine

Endocrine therapy

  • Concurrent systemic hormonal therapy for symptom control (e.g., appetite stimulation, pain, or nausea) allowed


  • See Disease Characteristics
  • See Chemotherapy
  • At least 4 weeks since prior radiotherapy for local disease and recovered


  • At least 3 weeks since prior major surgery


  • At least 2 weeks since prior anticancer therapy or investigational agents
  • The following drugs must not be used for 1-2 weeks before, during, and for 1-2 weeks after completion of study treatment:

    • Ketoconazole
    • Itraconazole
    • Ritonavir
    • Mibefradil
    • Clarithromycin
    • Saquinavir mesylate
    • Indinavir sulfate
    • Erythromycin
    • Nefazodone hydrochloride
    • Fluconazole
    • Diltiazem hydrochloride
    • Alfentanil hydrochloride
    • Carbamazepine
    • Cyclosporine
    • Tacrolimus
    • Lovastatin
    • Simvastatin
    • Any other drug known to be a potent inhibitor of cytochrome 3A4
  • No other concurrent anticancer therapy or investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00265876

Canada, British Columbia
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Ottawa Health Research Institute - General Division
Ottawa, Ontario, Canada, K1H 8L6
Algoma District Cancer Program
Sault Ste. Marie, Ontario, Canada, P6B 0A8
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
NCIC Clinical Trials Group
Study Chair: Malcolm J. Moore, MD Princess Margaret Hospital, Canada
Study Chair: Sharlene Gill, MD British Columbia Cancer Agency
  More Information

Responsible Party: NCIC Clinical Trials Group Identifier: NCT00265876     History of Changes
Other Study ID Numbers: I173
CDR0000450844 ( Other Identifier: PDQ )
Study First Received: December 14, 2005
Last Updated: November 25, 2016

Keywords provided by Canadian Cancer Trials Group:
adenocarcinoma of the pancreas
stage III pancreatic cancer
recurrent pancreatic cancer
stage IV pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017